What is known and objective: The off-label use of medicines is widespread in several diseases. This type of prescribing practice is particularly more acute in oncology. However, the suitability of anticancer medications for off-label use remains an issue of controversy, due to uncertainty around the clinical benefits and potential toxicities, limited evidence to support clinical decisionmaking, increased out-of-pocket costs for patients and ethical concerns around the lack of informed consent. Currently, data pertaining to the global prevalence of off-label use in cancer therapy are lacking. The aim of this review was to provide an overview of off-label drug use prevalence in oncology. Methods: A systematic literature search was performed in PubMed as per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines from 1975 to 2016. Studies assessing the prevalence of off-label use of anticancer drugs were included. Data synthesis: Of the 199 eligible papers retrieved, 23 studies were included in this systematic literature review. Off-label drug use in inpatients ranged from 18% to 41%. Among adult patients with cancer, 13%-71% received a minimum of one offlabel chemotherapy. The main reasons for off-label drug use were 'drug unapproved for specific tumour' and 'modified drug applications'. Among adults, metastatic cancers and palliative care patients received the most off-label drugs. The off-label drug use unsupported by standard treatment guidelines or drug compendia was in the range of 7%-31%. Conclusion: Off-label drug use in cancer therapy is commonly practised but outcomes could vary significantly. Hence, greater scrutiny and robust clinical guidance is needed to establish the favourable benefit-risk ratio for patients at the time of prescribing at each level of oncology care to facilitate rational off-label prescribing.
WHAT IS KNOWN AND OBJECTIVE
Off-label drug use refers to prescribing medicines in a manner that is inconsistent with prescribing information published by regulatory authorities. Off-label drug use can be classified into different categories, such as unapproved indication, use in a special population, through an unapproved route of administration or with a dose not specified in the FDA-approved label. 1 Off-label drug use based on little or no scientific evidence is termed as offevidence drug use. 2 For example, prescribing a drug for an indication in the clinical setting while the results of the clinical trial are not yet known. Off-label drug use is different from compassionate drug use. Compassionate drug use, also known as expanded access, facilitates the use of investigational therapies to individuals or groups of patients suffering from chronic, severely debilitating or deadly illness, who do not have access to suitable approved treatments or ineligible for clinical trials. 3 Off-label drug use is further differentiated from unlicensed drug use, which refers to the use of a therapeutic entity which has never received any regulatory approval for clinical use in either paediatrics or adult population (Table 1) . 1 Off-label prescribing is prevalent across different diseases and healthcare settings; however, it is more frequently reported in paediatrics, psychiatry and oncology. [4] [5] [6] Physicians are generally allowed to prescribe the drug in an offlabel manner in most regions in the world except in countries such as India where it is illegal. 7 The off-label status of a drug could also vary among different countries due to different marketing authorization timings or lack of drug approvals for newer indications.
Off-label prescribing may be advantageous in oncology as it presents evidence-based treatment options to patients who have no alternative options, for example in indications where there were no approved drugs or for patients who have exhausted standard lines of treatment. While off-label drug use may sometimes be clinically justified, it is associated with a number of safety and ethical issues. Off-label prescribing can jeopardize patient safety in certain clinical scenarios where a positive benefit-risk ratio is not fully established. 8 This is mainly due to the fact that off-label drug uses are not systematically appraised by regulators, guidelines formulators or even healthcare policymakers. Non-evidence-based off-label drug use carries toxicity risk. 9, 10 Several widely practiced off-label drug uses have also been found to be either harmful or ineffective when properly scrutinized. 11 An evaluation of 150 million off-label prescriptions revealed that 73% of off-label drug use was without strong scientific evidence. 12 Currently, there are no systematic literature reviews to date evaluating the prevalence and patterns of off-label prescribing in oncology. This information may be useful for healthcare policymakers, insurance companies, regulatory bodies and other stakeholders involved in regulatory or reimbursement decisions for anticancer medications. The aim of this systematic review was to provide an overview of off-label prescribing in cancer therapy from a global perspective. Specific aims include the following: assessing offlabel drug use in general, across different cancers and in different clinical settings, evaluating the reasons and characteristics associated with such practice and identifying commonly used medicines in an off-label manner. The review does not focus on off-label use of medications prescribed as supportive care in cancer.
METHODS
Search strategy for identification of studies. A search was conducted in the MEDLINE-PubMed database from January 1975 to June 2016. The search strategy included the following MeSH terms combined with Boolean operators: 'anticancer', 'chemotherapy', 'oncology' and 'off-label'. We did not use truncation or wild cards in the database searches to warrant automatic term mapping and explosion of MeSH terms. However, in advanced Google search, we conducted phrase searching by enclosing the phrases 'offlabel', 'chemotherapy', 'oncology' and 'anticancer' in double quotes. The study selection criteria required papers to be published in English and with those in other languages being excluded from the review. Furthermore, hand-searching of the bibliographies of potentially eligible articles was performed to identify additional studies. We also searched and included eligible conference abstracts from the database of American Society Clinical Oncology and European Society for Medical Oncology from inception to 2016.
Study selection. Studies were included if the primary objective was to assess the prevalence of off-label use of anticancer medications; the study reported the percentage of off-label prescriptions or percentage of patients receiving off-label prescriptions; the abstract or full text was available and provided sufficient information for review. Studies were not restricted by number of anticancer medication, cancer type or clinical setting. Preclinical research, phase 1 trial, pharmacokinetic or dose optimization studies, biomarkers research and meta-analysis were excluded from the review.
Risk of bias assessment. The heterogeneity of the included studies rendered available validated systematic quality assessment tools inappropriate. However, we appraised the full-text publications according to the following criteria. Conference abstracts were not rated. Any disagreements were resolved via discussion. Data extraction. Study details were extracted as follows: anticancer medication studied, type of cancer, data source, study design, study period, sample size, percentage off-label use, patients receiving off-label drugs were extracted. Off-label use was described by four categories: (i) unapproved drug for specific tumour group; (ii) unapproved drug for specific stage of disease (neoadjuvant, adjuvant, palliative and curative); (iii) unapproved line of treatment; (iv) modified application of drug (e.g. dose, frequency, combination, route of administration).
Data synthesis. The narrative synthesis of evidence was carried out based on the guidance provided by Popay et al. 13 We also studied other systematic review published on off-label prescribing for data synthesis.
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RESULTS
Selection and characteristics of studies. The search strategy identified a total of 3864 papers. Following screening, 199 papers were assessed as eligible, resulting in 23 studies being included in the review (Fig. 1) . The general characteristics of various studies, such as the extent and outcomes of off-label chemotherapies, are described in Table 2 . There were 23 studies reporting prevalence of off-label use. Off-label drug use was classified as category 1 (n = 16), [19] [20] [21] [22] [23] [24] [26] [27] [28] [30] [31] [32] [33] 36, 37, 39 category 2 (n = 10), [17] [18] [19] [20] [21] [22] 26, 29, 31, 32 category 3 (n = 12) [17] [18] [19] [20] [21] [22] 25, 26, 28, [37] [38] [39] and category 4 (n = 11). 18, 20, 21, 25, 27, 28, 31, 32, 34, 36, 39 Geographical distribution. Studies were conducted in nine countries: USA (n = 11), Italy (n = 3), France (n = 2), Australia (n = 2), Spain, Canada, China, Switzerland and Israel.
Risk of bias within studies. All the included studies have a clear study objective, definition and valid evaluation of off-label use. Off-label status of a drug use was correctly assessed using the prescribing information published by FDA. There was no use of formulary, guidelines, package inserts or books for defining offlabel use. Five studies gave limited or no information on baseline patient characteristics. 18, 19, 22, 25, 34 No study provide a rationale for sample size. Sample size was considered suboptimal for two studies considering the study objective. 36, 39 Three studies also provided limited descriptions of statistical methods or how they dealt with missing data and potential source of bias. 18, 22, 31 One study did not report results of multivariate analyses. 20 Two studies did not discuss the generalizability of their results.
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Off-label prescriptions. In general, 13%-71% of adult patients with cancer receives a minimum one off-label chemotherapy during the course of treatment. 18, 20, 21, 26, [31] [32] [33] [34] [35] Off-label drug use in hospitalized patients with cancer was in the range of 18%-41%. 20, 21, 26, 31, 35 For ambulatory care patients, 7%-50% of prescriptions were for off-label use. 32, 35 Off-label drug use unsupported by standard Reasons and therapeutic intents for off-label drug use. The main reasons for off-label drug use were 'lack of approved indication for specific tumour type' (9%-46%) and 'modified drug application' (10%-40%). 20, 31, 35 Off-label drug use with curative intent was reported to be in the range of 10%-41%, adjuvant setting was 8Á5%-49% and in palliative care was 34%-76%. 20, 32, 37 Eaton et al.
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, reported that in elderly patients with breast cancer, off-label regimens with adjuvant and neoadjuvant intents were 80% and 75%, respectively.
Off-label drug-use profile. The most commonly administered offlabel medicines were carboplatin, doxorubicin, fluorouracil, paclitaxel, docetaxel, vinorelbine, gemcitabine and oxaliplatin. 17, 18, [20] [21] [22] 30, 31, 33, [35] [36] [37] The most commonly used off-label targeted therapies include bevacizumab, trastuzumab, cetuximab, rituximab, gefitinib and erlotinib. [19] [20] [21] [22] 25, 28, 29, 34, 40 Bevacizumab was prescribed in an off-label manner for the treatment of metastatic colorectal cancer in a range of 10%-62% patients. 25, 28, 29 Off-label use of oral and intravenous anticancer drugs was reported to be 29% and 30%, respectively. 19, 23 Off-label use of patented drugs was reported to be 23% and 30% in two studies. 19, 22 Off-label drug use in different cancer stages and types. The patients with metastatic cancers found to be treated with off-label drugs were among 33%-65% of their overall population. 23, 37 Eaton et al. 17 reported that off-label regiments among breast cancer patients with stages 1, 2, 3 and 4 were 70%, 76%, 74% and 82%, respectively. Off-label drug use in colorectal cancer was in range of 6%-16%, lung cancer was 2%-14%, ovarian cancer was 19%, head and neck cancer was 26%, liver cancer was 11% and pancreatic cancer was 39%. 20, 21, 24, 26 Off-label regimens in patients with breast cancer ranged from 13% to 55% but could be as high as 78% among geriatric patients. 
DISCUSSION
This review suggests that off-label use is commonly practised across almost all cancer types. The rate of off-label prescribing was similar in the inpatient and outpatient setting. Palliative and metastatic cancer patients who had exhausted standard lines of treatment are most likely to receive drugs in such manner. This was expected as metastatic cancers are generally incurable and patients with good functional status receive off-label drugs following disease progression on approved treatment regimens. The main reason for off-label use was unapproved indication for specific tumour followed by use of the drug for unapproved line of treatment.
There are a myriad of reasons why off-label drug use is an indispensable practice in cancer therapy. These reasons are highly diverse and complicated. First, the data included in the prescribing information cannot guide clinical care of a diverse range of tumours types and patient characteristic in routine practice. As a result, many anticancer drugs are prescribed in altered doses, drug combinations, schedule of treatment, routes of administration and durations of therapy different from FDA-approved recommendations. Second, the phase III randomized clinical trials for orphan indications or uncommon tumours are often insufficiently powered to measure the significant impact on overall survival. For such cases, phase II trials may show the benefit of drugs and thus, those drugs may be implemented in clinical practice in an off-label manner. Third, there is a lag time between encouraging clinical trials findings, either published in peer-reviewed journals or reported at scientific symposia, the sponsor's new drug application for FDA review and the subsequent FDA authorization. Fourth, pharmaceutical companies are unwilling to apply for supplementary indications of previously approved drug in the market due to the expiration of the patent or lack of financial incentives. Going by the definition, if this medicine is being adopted by oncologists after the release of clinical trial results preceding FDA approval, this medicine can be considered as off-label drug use based on sound scientific evidence. Fifth, it is even possible that a drug approved for a cancer with specific gene expression is also active in patients having different types of genetic mutations. For example, crizotinib approved for anaplastic lymphoma kinase-rearranged non-small cell lung cancer was found to be efficacious in patients with c-ros oncogene 1 (ROS1) oncogene rearrangement. 41 Sixth, medical oncologists managing patients suffering with advanced or metastatic stage of disease are willing to try drugs with uncertain evidence outside clinical trials as a hope that these off-label drugs may offer prolonged survival frequently at the request of their patients. 2, 42, 43 Seventh, insufficient prescriber's knowledge of the existing FDA-approved drug labels also contributes to off-label use. 44 Oncologists generally rely on standard treatment guidelines or drug compendia for making treatment decisions. But as such compendia are inefficient and lacked methodological consistency and transparency in their review process. 45 A drug may exhibit different benefit-risk profiles in differing settings for the same cancer type. For example, in colorectal cancer, many drugs (including bevacizumab, Genentech U.S., Inc., San Francisco, CA, USA) that have proven efficacy in the metastatic setting but have failed to improve outcomes in the adjuvant treatment. 46 Despite this lack of clinical benefit, bevacizumab is still being prescribed in the adjuvant setting in colorectal cancer. 28, 29 Recently, a phase II trial found that off-label use of targeted agents provided no improvement in PFS compared with standard chemotherapy in heavily pretreated advanced cancer patients. 47 It is apparent that non-evidence-based off-label use might not provide any clinical benefits, but could potentially harm the patients. 48, 49 A 20% rate of hepatic sinusoidal obstructive syndrome was noticed when gemtuzumab, a drug approved as single agent for acute myelogenous leukaemia, was prescribed as an off-label chemotherapy treatment in combination with thioguanine. 50 Another example is the treatment of men who are at a high risk of prostate cancer using 5a-reductase inhibitors in an off-label manner to decrease cancer risk as suggested by the ASCO guidelines published in 2009. 51 This off-label use was however concluded to be dangerous as data from the REDUCE trial indicated an augmented risk of a more aggressive form of cancer with dutasteride therapy. This in turn prompted a drug safety alert published by FDA in 2011 for this toxicity concern. 52 Other data that highlighted the risk linked with off-label drug use include the systematic assessments within the postmarketing surveillance programmes by the RADAR (Research on Adverse Drug events And Reports) working group where those serious and unknown ADRs are often found to be occurring due to off-label drug use for which scientific evidence does not exist. 50 When there is inadequate evidence from trials, it becomes more difficult to determine whether there is sufficient value for off-label drug use to warrant successful reimbursement. 53 Considering the high cost of cancer treatments, the situation worsens when offlabel drugs are not reimbursed and would ultimately increase outof-pocket costs to patients. Oncologists have reported changing their therapeutic regimens due to reimbursement constraints resulting in poor access to medicines for patients with cancer. 37 In the USA, Medicaid would reimburse off-label drug use that is listed in compendia such as the American Hospital Formulary Service's Drug Information and Thomson Healthcare's Drug Points System. 54 Interestingly, few managed care establishments and private health insurance plans in the USA have refused to pay the cost of drugs used in an off-label manner to treat cancer disease stating that these clinical uses are 'experimental' or 'investigational'. Few countries such as the United Kingdom limit or reject access to unapproved drugs use on the grounds of lack of proven cost-effectiveness. 55 In Sweden, bortezomib (Takeda Oncology, Cambridge, MA, USA) and trastuzumab (Genentech U.S., Inc.,) were reimbursed by the National Reimbursement System for routine use at the choice of concerned medical oncologists, exemplifying their willingness to prescribe for off-labelled indications. 55 France recently opted for a new law called as 'Temporary Recommendations for Use' for provisionally overseeing the prescribing of drugs for unapproved indications and subsequent successful reimbursement in clinical practice. 56 Japan rejected reimbursement for off-label drug use while Italy changed its rule to facilitate use and reimbursement of cheaper off-label alternative such as bevacizumab in age-related macular degeneration. 57, 58 The regulation pertaining to practice of off-label drug use is not harmonized across the world. In the United States, off-label drug use can be legally prescribed but manufacturers are restricted from promoting the unapproved use of licensed drugs. 59 In 2006, the ASCO emphasized the necessity to update and completely apply the 'standard medical compendia' used by Medicare in the USA to cover designated, evidence-based, off-label use of oncology drugs. 54 Off-label prescribing is even legal in Europe, but each member state has own regulations. 60 The European Society of Medical Oncology has suggested the drug regulatory bodies to list standard off-label indications for anticancer drugs that could be approved by the European Medicines Agency. This mechanism would not resolve the whole problem at once, but it would, at least, streamline the condition and improve the physician's position particularly concerning the question of medical liability when challenged with the described contradictions of off-label drug use. 61 Many reforms have been suggested in different countries. In Japan, a drug can be licensed for off-label indication based on the evaluation of published literatures whereas China has recommended a grading mechanism for off-label indications. 62, 63 There is a general lack of consensus regarding the definition of offlabel drug use. Prescribing practices reported as 'off-label' in the literature years back might not be considered off-label today due to changes in prescribing information. Hence, the exact prevalence of off-label prescribing and comparisons of off-label prescribing then and now are difficult to assess and could also change over time. Our literature search was conducted solely in PubMed and excluded articles published in languages other than English. The studies were not pooled for meta-analysis owing to heterogeneities among them. For future research, an international study which examines the prevalence off-label drug use with a common definition is highly required. Also there is a need for comprehensive assessment of offlabel prescribing for paediatric populations, targeted therapies and cancer settings in developing countries.
CONCLUSION
It is evident from this review that off-label prescribing is indispensable in oncology and would not disappear soon as it is not possible to do clinical trials for each and every prescription and getting regulatory approvals for it. However, the health systems could be structured to maximize the likelihood of a favourable benefit-risk ratio for patients under robust clinical governance guidelines which work across all the care settings, prescribing, supply, administration and reimbursement.
